Principia Biopharma Receives $50,000,000 Series B Funding

  • Feed Type
  • Date
    4/22/2014
  • Company Name
    Principia Biopharma
  • Mailing Address
    400 East Jamie Court South San Francisco, CA 94080 USA
  • Company Description
    Principia is committed to changing the drug development paradigm. The company’s reversible covalent technology platform rapidly and reliably produces compounds with superior selectivity, enabling development of multiple product candidates with substantial commercial potential.
  • Website
    http://www.principiabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds from this financing will be used to further advance the company’s pipeline, including an oral BTK inhibitor for potential use in autoimmune disease and oncology, an oral, selective, irreversible FGFR inhibitor program for the treatment of solid tumors, an oral IL-17 pathway inhibitor program with utility across a range of autoimmune and inflammatory diseases as well as helping Principia expand into a clinical stage company.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor